Clinical Trial Update: Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL) [Phase 1]

View source ↗

Summary

This Phase 1 trial assessed safety, tolerability, and maximum tolerated dose of BI 2536 in patients with recurrent advanced aggressive non-Hodgkin lymphoma; the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• BI-2536

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Lymphoma | Phase 1 | Status: COMPLETED